TerminatedNot Applicable

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Stopped: Patient accrual was slow due to exclusion of patients with prior cancers

United States39 participantsStarted 2016-06

Plain-language summary

Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the utility of molecular diagnostic assays for the early detection of lung cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older, not previously diagnosed with cancer (except for basal cell carcinomas of the skin or a diagnosis of cancer within a month of surgery and for which the surgical procedure is being performed). Exclusion Criteria: * Prior history of cancer.

What they're measuring

Percentage of patients with lung cancer who had a positive ctDNA result (true positive)

Timeframe: 5 years

Trial details

NCT IDNCT02715102

SponsorPathway Genomics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-08

View on ClinicalTrials.gov More Cancer of the Lung trials